Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Angelalign Technology Inc. (6699.HK)
Shanghai, CN
Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner Pro and Angel Aligner Classic, are bespoke, removable clear aligners designed to gradually guide a patient's teeth into proper alignment over time. Beyond aligner development, the company also operates dental clinics that provide a variety of services, including orthodontics and cosmetic dentistry, and distributes intraoral scanners. Their extensive portfolio of clear aligner brands features Angelalign, Angelalign Pro, Angelalign Kid, and COMFOS. The firm was founded in 2003 and maintains its principal offices in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50% | -2.56% | -21.40% | -6.88% | +13.10% | +18.04% | +24.96% | -4.74% | -82.46% | -82.46% | -82.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+32.2% ★ Q2'25: +34.2% (vs Q2'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%+131.4% ★ Q2'25: +365.5% (vs Q2'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+4.4% Q2'25: +0.5% (vs Q2'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+6.3% Q2'25: +6.1% (vs Q2'24)
-
ROIC Medical - Instruments & Supplies: +6.0%— Q2'25: -0.6% (vs Q2'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%0.0% Q2'25: +0.3% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.06× ★ Q2'25: 0.07× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 6 EPS Ana. |
Dec 2027 10 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.27B
est: 1.42B (-10.3%)
|
1.27B
est: 1.38B (-7.9%)
|
1.48B
est: 1.60B (-7.8%)
|
1.96B
est: 1.84B (+6.7%)
|
2.59B
est: 2.40B (+7.9%)
|
3.09B
3.00B – 3.12B
+28.6% YoY
|
3.71B
3.57B – 3.85B
+20.0% YoY
|
4.40B
4.26B – 4.52B
+18.7% YoY
|
| EBITDA |
372.47M
est: 272.95M (+36.5%)
|
318.65M
est: 265.44M (+20.0%)
|
154.39M
est: 256.48M (-39.8%)
|
77.34M
est: 294.43M (-73.7%)
|
293.27M
est: 385.06M (-23.8%)
|
495.02M
480.52M – 500.59M
+28.6% YoY
|
594.05M
572.35M – 617.10M
+20.0% YoY
|
705.22M
681.78M – 723.74M
+18.7% YoY
|
| EBIT |
333.31M
est: 210.54M (+58.3%)
|
253.42M
est: 204.75M (+23.8%)
|
69.18M
est: 182.65M (-62.1%)
|
-2.93M
est: 209.67M (-101.4%)
|
164.24M
est: 274.21M (-40.1%)
|
352.52M
342.20M – 356.48M
+28.6% YoY
|
423.04M
407.59M – 439.45M
+20.0% YoY
|
502.21M
485.52M – 515.39M
+18.7% YoY
|
| Net Income |
285.85M
est: 384.85M (-25.7%)
|
213.78M
est: 205.60M (+4.0%)
|
53.48M
est: 40.60M (+31.7%)
|
88.42M
est: 61.99M (+42.6%)
|
199.13M
est: 202.05M (-1.4%)
|
185.70M
123.15M – 248.26M
-8.1% YoY
|
303.11M
246.90M – 359.32M
+63.2% YoY
|
424.19M
348.46M – 499.92M
+39.9% YoY
|
| SGA |
419.70M
est: 574.39M (-26.9%)
|
483.20M
est: 558.58M (-13.5%)
|
772.74M
est: 596.75M (+29.5%)
|
1.10B
est: 685.05M (+61.1%)
|
173.61M
est: 895.91M (-80.6%)
|
1.15B
1.12B – 1.16B
+28.6% YoY
|
1.38B
1.33B – 1.44B
+20.0% YoY
|
1.64B
1.59B – 1.68B
+18.7% YoY
|
| EPS |
0.30
est: 2.28 (-86.8%)
|
1.28
est: 1.21 (+6.1%)
|
0.32
est: 0.24 (+32.5%)
|
0.53
est: 0.37 (+43.8%)
|
1.18
est: 1.16 (+1.6%)
|
1.17
0.73 – 1.47
+1.0% YoY
|
1.76
1.46 – 2.13
+50.3% YoY
|
2.66
2.06 – 2.96
+50.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.35% | 225.5K | 0.59% |
| 2 | Amundi MSCI China Tech UCITS ETF USD CC1U.L | 0.22% | 636.8K | 0.55% |
| 3 | Amundi MSCI China Tech UCITS ETF EUR CC1.PA | 0.22% | 635.9K | 0.55% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.05% | 35.6K | 0.74% |
| 5 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 141.6K | 0.72% |
| 6 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 114.2K | 0.74% |
| 7 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 218.2K | 0.65% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 31.9K | 0.42% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 136.6K | 0.55% |
| 10 | State Street SPDR S&P China ETF GXC | 0.02% | 88.4K | 0.59% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jiezhang Hu | Chief Executive Officer, Chief Technology Officer & Executive Director | 5M | male |
| Xin Song | Chief Strategy Officer | 4M | male |
| Li Dong | Chief Financial Officer & Executive Director | 4M | female |
| Kun Huang | Executive Director & President of Non-China Global Business | 2M | male |
| Leong Yin Lee | Company Secretary | — | male |
| Dai Feng | Executive Chairman of the Board | — | male |
| Richard S. Hirschland | Senior Vice President & Global Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6699.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
